Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
2期
进行中（已停止招募）
NCT02143414
| 适应症 | Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t; BCR-ABL1, Recurrent Acute Lymphoblastic Leukemia |
|---|
| 分期 | 2期 |
|---|
| 申办方 | National Cancer Institute (NCI) |
|---|
| 状态 | 进行中（已停止招募） |
|---|
| 受试者人数 | 53 人 |
|---|
| 干预（药物） | Biopsy Procedure, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Computed Tomography |
|---|
| 开始日期 | 2015年6月30日 |
|---|
| 完成日期 | 2022年6月1日 |
|---|
| 结果公布日 | 2023年1月25日 |
|---|
摘要
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.
Overall Survival Rate (Cohort I)
From the day of registration on study until death from any cause, assessed at 3 years · percentage of participants
| Cohort I (Ph-) | 34 percentage of participants |
|---|
Incidence of Dose-limiting Toxicity (Cohort II)
Up to day 42 of post-remission therapy · Participants
| Cohort II (Ph+/Ph-like) | 0 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。